Aptinyx Inc. (APTX): Price and Financial Metrics
APTX Price/Volume Stats
| Current price | $0.10 | 52-week high | $0.72 |
| Prev. close | $0.09 | 52-week low | $0.01 |
| Day low | $0.09 | Volume | 231,100 |
| Day high | $0.10 | Avg. volume | 1,317,051 |
| 50-day MA | $0.07 | Dividend yield | N/A |
| 200-day MA | $0.08 | Market Cap | 6.50M |
APTX Stock Price Chart Interactive Chart >
Aptinyx Inc. (APTX) Company Bio
Aptinyx Inc. develops therapeutics for neurological disorders. The company is focused on the development of drugs that interact with the NMDA receptor, and the company says it will use the funds to advance drugs for chronic pain, post-traumatic stress disorder (PTSD) and cognitive impairment in Parkinson’s disease. The company was founded in 2015 and is based in Evantson, Illinois.
Latest APTX News From Around the Web
Below are the latest news stories about APTINYX INC that investors may wish to consider to help them evaluate APTX as an investment opportunity.
Horizon (HZNP) Q1 Earnings and Revenues Miss EstimatesHorizon Therapeutics (HZNP) reports lower-than-expected first-quarter 2023 results as it misses the Zacks Consensus Estimates for both revenues and earnings. |
Anixa (ANIX) Falls 25% Despite Positive Breast Cancer Study DataAnixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports. |
Agenus (AGEN) Rises on Fast Track Tag for Cancer Combo DrugThe FDA grants Fast Track Designation to Agenus' (AGEN) phase II study evaluating the botensilimab/balstilimab combination in non-MSI-H colorectal cancer patients. The stock jumps 16% following the news. |
Adaptimmune (ADAP) Up 7%, Gets T-Cell Programs Rights From GSKAdaptimmune Therapeutics (ADAP) enters into a transition deal with GSK to regain rights to its proprietary T-cell therapy programs. Shares of the company surges 7% following the news. |
Merck (MRK) Keytruda Studies in Difficult-to-Treat Cancers FailMerck (MRK) and Eisai announce the discontinuation of the phase III LEAP-003 study seeking approval of the Keytruda and Lenvima combo. Another phase III LEAP-017 study fails to meet goals. |
APTX Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | 55.52% |
| 1-year | -20.00% |
| 3-year | -96.32% |
| 5-year | -97.27% |
| YTD | 4.17% |
| 2023 | -66.35% |
| 2022 | -89.31% |
| 2021 | -22.83% |
| 2020 | 1.17% |
| 2019 | -79.32% |
Continue Researching APTX
Want to see what other sources are saying about Aptinyx Inc's financials and stock price? Try the links below:Aptinyx Inc (APTX) Stock Price | Nasdaq
Aptinyx Inc (APTX) Stock Quote, History and News - Yahoo Finance
Aptinyx Inc (APTX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...